Probiotics

Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefit on the host. The field has been substantially limited by strain specificity: evidence for one specific strain cannot be reliably extrapolated to another strain, even within the same species. A validated clinical trial for Lactobacillus rhamnosus HN001 does not translate to benefit from a generic “Lactobacillus rhamnosus” product, because different strains express different surface proteins, produce different metabolites, and colonize different niches.

Strains with the strongest human RCT evidence include L. rhamnosus HN001 (perinatal anxiety and depression with OR 0.44, Slykerman et al., 2017), B. longum NCC3001 (IBS-related depression with fMRI-confirmed CNS changes, Pinto-Sanchez et al., 2017), B. longum 1714 (stress response and memory, Allen et al., 2016), and L. helveticus R0052 plus B. longum R0175 combination (depression, anxiety). Multi-strain products like Ecologic Barrier 825 have evidence for depression symptoms. Saccharomyces boulardii has strong evidence for antibiotic-associated diarrhea and C. difficile prevention.

Product selection principles: identify products by specific strain designation (e.g., “HN001”) not just species name, verify CFU counts at end-of-shelf-life not manufacture (many products lose potency over time), confirm refrigeration requirements, and match strain to indication based on clinical trial evidence. Duration of at least 8 weeks is typical for mood and IBS indications; acute infectious diarrhea responds within days. Probiotics are not universally safe: in critically ill or immunocompromised patients, probiotic-induced sepsis has been reported, and routine use in these populations should involve clinical oversight.